The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

Abstract

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

Keywords

multiple sclerosis neuroprotection riluzole

Get full access to this article

View all access options for this article.

References

Ferguson B , Matyszak MK , Esiri MM , Perry VH. Axonal damage in acute multiple sclerosis lesions . Brain 1997; 120(Pt 3): 393-399 .

Trapp BD , Peterson J , Ransohoff RM , Rudick R , Mork S , Bo L. Axonal transection in the lesions of multiple sclerosis . N Engl J Med 1998; 338: 278-285 .

Scolding N , Franklin R. Axon loss in multiple sclerosis . Lancet 1998; 352: 340-341 .

van Waesberghe JH , Kamphorst W , De Groot CJ , et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability . Ann Neurol 1999; 46: 747-754 .

Pitt D , Werner P , Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis . Nat Med 2000; 6: 67-70 .

Werner P , Pitt D , Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage . Ann Neurol 2001; 50: 169-180 .

Bensimon G , Lacomblez L , Meininger V , ALS/Riluzole Study Group . A controlled trial of riluzole in amyotrophic lateral sclerosis . N Engl J Med 1994; 330: 585-591 .

Stevenson VL , Leary SM , Losseff NA , et al. Spinal cord atrophy and disability in MS: a longitudinal study . Neurology 1998; 51: 234-238 .

Coles AJ , Wing MG , Molyneux P , et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis . Ann Neurol 1999; 46: 296-304 .